H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Genmab (GMAB) to $37 from $50 and keeps a Buy rating on the shares following the Q4 report.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
- Genmab A/S Advances Share Buy-back Program as of April 2025
- Genmab Discloses Managerial Share Transactions
- Genmab downgraded to Underperform from Market Perform at Bernstein
- Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns